Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting two posters at the American Association for Cancer Research (AACR) Annual Meeting 2022 being held in New Orleans, Louisiana, from April 8-13. The posters to be presented at AACR are developed from the investigational nucleic acid platform, UNITE™ (UNiversal Intracellular Targeted Expression) for two vaccines, ITI-3000 for Merkel cell carcinoma and Her2/Neu-LAMP DNA vaccine, both which fuse a tumor associated antigen with lysosomal associated membrane protein 1 (LAMP-1). This proprietary lysosomal targeting technology results in enhanced antigen presentation and a balanced T cell response.
“Both ITI-3000 and Her2/Neu-LAMP DNA vaccines are innovative and novel targeted approaches,” says Teri Heiland, Ph.D., Immunomic’s Chief Scientific Officer. “We are highly encouraged by the data and look forward to a first-in-human trial for ITI-3000, a vaccine for Merkel cell carcinoma, and further pre-clinical development for Her2/Neu-LAMP vaccine.”
Poster Title: LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses, tumor inhibition, and provides rationale for first-in-human trial
Session Category: Immunology
Session Title: Immune Response to Therapies 1
Session Date and Time: Monday April 11, 2022, 1:30 PM - 5:00 PM ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Poster Number: 10
-----------------------------------------------------------------------------------------------------------------------------------------
Poster Title: Harnessing soluble CD40L to enhance anti-tumor efficacy of Her2-LAMP DNA vaccine using UNITE™ platform
Session Category: Immunology
Session Title: Vaccines: Oncolytic and Prophylactic
Session Date and Time: Tuesday April 12, 2022, 1:30 PM - 5:00 PM ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 40
Poster Number: 3
Poster Availability: e-Posters will be on display in the AACR Gallery
About UNITE
ITI’s investigational UNITE platform, UNiversal Intracellular Targeted Expression, leverages the ability to engineer chimeric proteins, directing antigen presenting cells to present antigens to the immune system through a targeted pathway and driving a robust immune response. UNITE vaccines are distinct in that they combine two components: nucleic acid constructs that encode a specific antigen and an endogenous Lysosomal Associated Membrane Protein (LAMP-1) sequence. The UNITE platform harnesses LAMP-1 as a means of presenting the vaccine target to the immune system, resulting in antibody production, inflammatory cytokine release, and establishing critical immunological memory, something that other vaccine approaches commonly lack. This approach could put UNITE technology at the crossroads of immunotherapies in multiple indications, including cancer, human allergy, animal health, and infectious disease. Preclinical data is currently being developed to explore whether LAMP-1 nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and used to create immune responses in tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the body’s natural biochemistry to develop vaccines that generate broad immune responses. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. ITI maintains its headquarters in Rockville, Maryland. For more information, please visit www.immunomix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005007/en/
Contacts
Company:
Melissa Kemp
mkemp@immunomix.com
301-968-3501
ITI Media:
Melody Carey
mcarey@rxir.com
917-322-2571
